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 3 
Impact of findings on practice 4 
 Medical practice staff were effective at signposting poorly controlled patients to 5 
the drop-in clinic. 6 
 Increased collaboration with the medical practice and the presence of a second 7 
pharmacist to support dispensary activities may be necessary to facilitate this 8 
kind of service.  9 
 Pharmacists made a number of recommendations to participants and medical 10 
practices and the clinic was highly regarded by both participants and 11 
pharmacists. 12 
  13 
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Introduction 14 
An estimated 17.5 million people were diagnosed with a long term condition in the 15 
UK in 2005 [1]. In 2009, 2.1 million were diagnosed with type 2 diabetes and this 16 
figure is predicted to rise to 3.2 million (5.9% prevalence) by 2020 [2]. The majority of 17 
patients (85%) are diagnosed with type 2 diabetes which is largely controlled by oral 18 
medication [3].  19 
 20 
The main clinical marker for type 2 diabetes is HbA1C which, according to national 21 
guidelines should be maintained below 7.5% [3]. However, recent UK National Health 22 
Service (NHS) figures suggest that approximately only 65% of patients are achieving 23 
this target, along with only 40% of patients achieving their target blood pressure and 24 
42% their target cholesterol [4]. In the UK, the National Institute for Health and Care 25 
Excellence (NICE), has published guidelines for the management of patients with 26 
type 2 diabetes, which includes prescribing guidelines for blood pressure and 27 
cholesterol treatment [3]. An audit of prescribing for type 2 diabetes has 28 
demonstrated that it is generally in accordance NICE guidance [5]. Therefore, the 29 
failure of patients to achieve therapeutic targets may be related to medicine doses 30 
not being optimised or sub-optimal medication adherence as well as diet and lifestyle 31 
problems. 32 
 33 
In 2008, an average adult visited a community pharmacy 16 times per year with 86% 34 
of the population visiting at least once per year, 78% of those for health-related 35 
reasons [6], thereby providing an opportunity for monitoring and intervention. With 36 
the emphasis on both the prescribing of correct medicines and the need for patients 37 
to adhere to their medicines, it seems appropriate that a pharmacist can contribute to 38 
the care of patients with type 2 diabetes. The majority of patients with type 2 diabetes 39 
will be treated with medication dispensed from a community pharmacy in primary 40 
care.  41 
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 42 
In several UK Government policy documents, community pharmacy is specifically 43 
targeted as a profession that can be used to improve the care of patients with long 44 
term conditions [1, 6, 7]. Pharmacists are already engaged in providing Government-45 
funded, non-appointment based adherence interventions such as the medicine use 46 
reviews (MUR) to patients with chronic conditions. The MUR is a consultation 47 
generally lasting up to 20 minutes during which the patient is given the opportunity to 48 
discuss their thoughts and experiences of their prescribed medicines.  If any 49 
problems are identified, the pharmacist then agrees a strategy for resolution which 50 
may include referral back to the patient’s physician. This review does not require 51 
access to the patient’s medical notes. These services are not condition specific and 52 
have a relatively limited evidence base. It may, therefore, be more appropriate to 53 
target a specific condition and provide a more tailored service than those currently 54 
offered.  55 
 56 
International studies have highlighted that the community pharmacist may have a 57 
role in addressing adherence and other concerns in this population of patients 58 
leading to improved blood glucose control [8-15]. A UK study has indicated a 59 
significant difference in HbA1C between the intervention and control groups using 60 
RCT methodology in two pharmacies [16]. The intervention, aimed at poorly 61 
controlled patients with type 2 diabetes, involved regular monitoring and 62 
consultations with the community pharmacist for 12 months for a total of six 63 
consultations. The study was mainly conducted in one pharmacy with two permanent 64 
pharmacists and a part time nurse. It consisted of a targeted medicine use review to 65 
discuss any adherence problems if appropriate, lifestyle modification and referral to 66 
the GP if necessary. It also included education about diabetes and its complications. 67 
This was an intensive, repeated intervention service with significant time input and no 68 
cost effectiveness analysis [16]. We believe, to make this service widely available to 69 
patients there would need to be significant change to the ways pharmacists are 70 
currently remunerated. This is because UK pharmacy remuneration is dominated by 71 
fees for dispensing medicines thus spending long periods of time with patients 72 
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means fewer prescriptions can be checked or dispensed. An alternative funding 73 
approach would be to take the existing MUR framework (which only requires a one-74 
off, 20 minute consultation) and make it more specific to patients with diabetes. This 75 
will be a small step change in the provision of pharmacy services that would not 76 
require a significant operational restructure. 77 
 78 
In a series of focus groups with patients with type 2 diabetes, participants drawing on 79 
their experience of living with diabetes indicated that they would be willing to engage 80 
with a community pharmacy service aimed at improving their condition providing that 81 
the pharmacist was working in co-operation with the medical practice and they were 82 
not violating the natural line of treatment between them and the doctor [17]. 83 
 84 
All participants in these focus groups identified that they wanted to take responsibility 85 
for their own condition but occasionally they had needs for information and wanted to 86 
be able speak to a suitably qualified healthcare professional. As such, participants 87 
liked the ease and convenience of speaking to the pharmacist and the lack of need 88 
for appointment bookings.  89 
 90 
This preparatory work led to the design of a diabetes drop-in clinic in the community 91 
pharmacy setting that involved identification of poorly controlled patients by the 92 
medical practice, no appointment system and a focus on adherence and lifestyle 93 
advice. This paper provides details on the results of a feasibility study.  94 
 95 
Aims of the study 96 
To determine whether a community pharmacy diabetes drop-in clinic is feasible and 97 
acceptable to patients with poorly controlled type 2 diabetes and assessing which 98 
outcome measures would be appropriate for a larger study and describing the 99 
content of the consultations.  100 
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 101 
Ethical Approval 102 
Essex NHS Research Ethics Committee (Ref: 11/EE/0494) and NHS Norfolk 103 
Research and Development committee (Ref: 2011IC01) approved this study.  104 
 105 
Method 106 
As this was a feasibility study, community pharmacies and medical practices were 107 
selected based on convenience and contacts that existed between pharmacists and 108 
the academic institution.  109 
 110 
The diabetes pharmacy drop in clinic specifically targeted patients who were poorly 111 
controlled with respect to one or more of HbA1C (>59 mmol/mol), blood pressure 112 
(>140/80mmHg) or lipids (>5 mmol/L) as defined by a national incentive scheme. 113 
Medical practice staff identified eligible patients on behalf of the research team. The 114 
staff were provided with pre-filled envelopes enclosing a letter from the practice 115 
partners and a leaflet advertising the service and were asked to mail these to all 116 
identified poorly controlled patients. The leaflet contained information including clinic 117 
times and what was involved when patients attended the pharmacy. The researcher 118 
had no access to medical records for this process. Informed patient consent was 119 
obtained when the patient presented in the pharmacy and this allowed the 120 
pharmacist to collect biometric data from the medical practice for the purposes of the 121 
research. 122 
 123 
The clinic was conducted in five pharmacies with the regular pharmacist in the 124 
private consultation room located in the pharmacy. Two pharmacies used a 125 
consultation room in the adjoining medical practice as they did not have one on the 126 
pharmacy premises. This was usual practice for those pharmacists when conducting 127 
MURs. Pharmacists were given extra training in order to provide the service which 128 
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included a self-directed learning package and a short face-to-face session with the 129 
lead researcher. The clinic was conducted for a four-hour period once a week for four 130 
weeks (six weeks in one pharmacy) and patients were able to attend without making 131 
a prior appointment. The clinic times were selected to ensure that a variety of days of 132 
the week (including Saturdays) and times (morning and afternoon) were covered. 133 
The aim was to recruit 30-40 participants between the five pharmacies. A second 134 
pharmacist (MT) provided dispensary support to the intervention pharmacist. Patients 135 
also had the opportunity to visit the pharmacy outside of the clinic times but were 136 
informed that they may have to wait a short while to see the pharmacist.  137 
 138 
Before undertaking the consultation participants were asked to complete a short 139 
questionnaire containing three validated questionnaires: the Beliefs about Medicines 140 
Questionnaire (BMQ) [18], the Satisfaction with Information about Medicines 141 
questionnaire (SIMS) [19] and Morisky measure of adherence (MMAS-4) [20] 142 
combined with questions regarding how many times and why they have used the 143 
community pharmacy over the preceding three months. The MMAS-4 is composed of 144 
four questions surrounding a patient’s medicine taking behaviours. A score of 4 on 145 
this scale is interpreted as the patient being fully adherent while less than four 146 
indicates partial adherence. This information was then used by the pharmacist during 147 
the consultation with the participant. These outcome measures were selected as the 148 
service was designed based on existing community pharmacy services which largely 149 
involve information provision and adherence advice. There is evidence to suggest 150 
that information satisfaction is related to adherence [19] and that this can also be 151 
related to a patient’s beliefs and concerns surrounding a particular medicine [21]. 152 
 153 
The consultation was then conducted by the community pharmacist in the 154 
consultation room for a duration determined by the patient. The pharmacist was 155 
asked to document the content of the consultation on a standard form. As a feasibility 156 
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study and based on the literature, the focus of the interaction was not prescribed by 157 
the research team but led by the patient from their discussion with the pharmacist 158 
and their responses to the baseline questionnaire.  159 
 160 
Post consultation, the participants were asked to complete a satisfaction 161 
questionnaire which contained questions regarding the conduct of the pharmacist, 162 
the surroundings in which the consultation occurred and their opinions on the 163 
consultation. This was posted directly to the lead researcher at the university to 164 
minimise social desirability bias which could result from posting to the community 165 
pharmacy.  166 
 167 
Three months post consultation, patients completed a repeat of the baseline 168 
questionnaire which was posted to their address and returned in a pre-paid envelope 169 
to the University.  Non-return resulted in a full repeat posting after two weeks. 170 
 171 
After study completion, all pharmacists undertook a de-brief interview with the lead 172 
researcher regarding their thoughts and experiences related to the service. This was 173 
conducted as individual interviews and pharmacists provided written consent to be 174 
recorded.  175 
 176 
The pharmacist interviews were transcribed and coded by the researcher and 177 
themes were developed using content analysis as described in the literature [22]. A 178 
second researcher also read the transcripts and familiarised themselves with the 179 
participants responses. The two researchers had discussions surrounding the 180 
themes to arrive at a consensus and resolve any conflicting views. 181 
 182 
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Results 183 
Five pharmacies (three independents and two chain pharmacies) and three medical 184 
practices were recruited in three locations across Norfolk, UK. Two of the three 185 
independent pharmacies were owned by the medical practice that also participated in 186 
the project. None of the medical practices had an established relationship with the 187 
academic institution at the outset of the study.  188 
 189 
The medical practices identified and posted the invitation letter and information sheet 190 
to 342 potential participants. Thirty-three participants (9.6% response rate) were 191 
recruited in four of the five pharmacies with each pharmacy seeing between zero and 192 
five participants during each four-hour session. The demographics of the recruited 193 
participants are detailed in table 1. The mean (SD) time for the consultation was 32.5 194 
(12.0) minutes but ranged from 15 minutes to 65 minutes. As part of the 195 
consultations, pharmacists discussed a wide variety of topics and made a number of 196 
referrals to the medical practice including: 197 
 198 
 Providing information sheets on diet and lifestyle 199 
 Advising participants on portion size 200 
 Information provision on medication 201 
 Identification and reporting of adherence issues 202 
 Changes to formulation to aid adherence 203 
 Requests for alternative or additional medicines for cholesterol and other 204 
conditions 205 
 206 
 207 
Insert table 1. 208 
 209 
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All participants completed the baseline questionnaire and the team received 26 210 
(79%) follow-up questionnaires. There was no difference in any of the questionnaire 211 
measures between baseline and follow-up (tables 2 and 3) apart from the types of 212 
topics that participants were prepared to talk to the pharmacist about. The number of 213 
patients classed as adherent rose from 61.5% at baseline to 76.9% at follow-up. 214 
 215 
Insert tables 2 and 3. 216 
 217 
Satisfaction questionnaire 218 
In total, 27 completed questionnaires were returned. These results demonstrate that 219 
participants were extremely satisfied with the service that they received and they 220 
most would recommend the service to another patient with type 2 diabetes. In 221 
response to the question regarding how useful the service was to helping manage 222 
their diabetes, 100% agreed that it was some or a lot of help. Nearly 60% of 223 
participants stated that this experience would make them more likely to consult their 224 
pharmacist in future about other conditions with nearly 90% stating that the length of 225 
the consultation was about right. A summary of the other questions asked can be 226 
found in figure 1 and demonstrates that all aspects of the service and study process 227 
were well received.  228 
 229 
Insert figure 1. 230 
 231 
Pharmacist de-brief interviews                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              232 
The pharmacist debrief interviews centred on three areas of discussion: training 233 
provision, conduct of the service and the benefits arising from the service.  234 
 235 
Training provision 236 
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The participating pharmacists identified that the training provision for the service 237 
which consisted of a self-directed learning package and a short face-to-face training 238 
session was adequate to cover their needs for the study. As part of the face-to-face 239 
element, pharmacists were informed of the previous work from the focus groups with 240 
patients. This helped them to contextualise the clinic within their practice and tailor 241 
their consultations with this information in mind. One pharmacist identified that, in her 242 
opinion, interaction with her peers would have been useful to determine how each of 243 
them was going to implement the service and what they had learnt as a result of the 244 
training in diabetes and study documentation thus far whereas another pharmacist 245 
wanted interaction with other healthcare professionals.  246 
 247 
“I personally would’ve liked... time with either the diabetes nurse or one of the 248 
doctors at the practice er just to clarify er sort of their guidelines and what 249 
they were trying to achieve with their patients.” Pharmacist 3 250 
 251 
There was a need for this pharmacist to integrate further with the medical practice 252 
and determine their patterns and guidelines for treatment as he did not want to go 253 
against the wishes of the practice nurse or GP when making suggestions to them for 254 
treatment alterations.  255 
 256 
Conduct of the service 257 
Once in the consultation, pharmacists identified a number of topics that patients 258 
wanted to cover and these varied for each pharmacist. 259 
 260 
“Quite a few people wanted to know about like the prognosis of 261 
diabetes…they didn’t quite realise that they would be on medication for like a 262 
long time” Pharmacist 2 263 
 264 
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This pharmacist appeared surprised at the content of the consultation, expecting 265 
participants to focus on medicines but instead wanting to discuss other matters 266 
surrounding their condition. With the pharmacist below, their perception was that 267 
participants just wanted reassurance that they were doing the right things to control 268 
their diabetes.  269 
 270 
“I think most people came with some ideas, some had things they just wanted 271 
reassurances about other people just came to say their diabetes is fine and 272 
explain their medications...” Pharmacist 5 273 
 274 
The pharmacists felt that because of this wide variation in topics covered during the 275 
consultation, this meant they were sat with the patient for an extended period of time, 276 
which they felt had its benefits but could only be achieved because another 277 
pharmacist was covering their dispensary workload. 278 
 279 
“They don’t normally get to spend a long time talking to the doctor or nurse, 280 
they are often rushed… I think it’s quite well received by patients...I think it 281 
would be very difficult to run that kind of service if I didn’t have any locum 282 
cover or second pharmacist cover... they [patients] feel less intimidated 283 
disturbing what you are doing.” Pharmacist 5 284 
 285 
This statement confirmed that the pharmacists would not have been able to conduct 286 
this service had a second pharmacist not been available to them, it allowed them to 287 
focus on the needs of the patient as well as completing all of the relevant paperwork 288 
required for the study.  289 
 290 
Benefits arising out of the study 291 
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Pharmacists identified that participating in this study had benefits to patients, 292 
themselves as healthcare professionals and their interaction with the medical 293 
practice. Pharmacists highlighted that a positive aspect of the study was that they 294 
had had participants return to them after the consultation to update them on their 295 
progress, which is something that, as pharmacists, they are not used to.  296 
 297 
“…we’ve already had somebody come in this morning to say how his levels… 298 
have improved as a result of just having a chat. I think it is fantastic if we… 299 
get away from checking prescriptions and providing a service like this its 300 
great” Pharmacist 4 301 
 302 
Most pharmacists highlighted that participating in the study was beneficial to their 303 
wider practice as well as the drop-in clinic and that it had given them more 304 
confidence to speak to this group of patients. One final benefit that was highlighted 305 
was the increased collaboration with the medical practice. 306 
 307 
“I think it has strengthened the link with the diabetes nurses ‘cause a lot of the 308 
time we have had further questions about a patient whose medication I 309 
couldn’t change and I’ve referred to the diabetes nurse… it’s a been a good 310 
link” Pharmacist 5 311 
 312 
All of the pharmacists saw this kind of service as benefitting the relationship with the 313 
medical practice and demonstrating where the community pharmacist could help 314 
when trying to control patients with type 2 diabetes. They also stated that this would 315 
help to raise the profile of pharmacy more generally within the medical practice, 316 
which could only be positive for pharmacy.  317 
 318 
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Discussion 319 
The primary aim of this study was to determine if a drop in clinic based on patient 320 
preferences aimed at those with poorly controlled type 2 diabetes and conducted in 321 
the community pharmacy was feasible and acceptable to patients and pharmacists. It 322 
has demonstrated that patients will access community pharmacy services if identified 323 
via the medical practice and that they have significant information needs in relation to 324 
their condition and medicines that can be addressed by the pharmacist. It also set 325 
out to examine which outcome measures may be appropriate in a future study and 326 
ascertain the focus of the consultation.  327 
 328 
In terms of feasibility testing, this study has been successful. The medical practices 329 
were willing to approach patients on behalf of the service, pharmacists could conduct 330 
the consultations and patients found them acceptable and were willing to engage 331 
with the process. However, this study could only be conducted with a second 332 
pharmacist that allowed the intervention pharmacist to spend the length of time they 333 
did with the participants and is unclear how cost-effective this would be on a larger 334 
scale. It would also need to be investigated whether this length of time spent with the 335 
patient represents a good use of resources. On reflection, the one pharmacy that did 336 
not recruit any patients felt that this was due to the lack of prescription volume from 337 
the medical practice associated with the study.  338 
 339 
Questionnaire results from baseline to follow-up demonstrated no differences in the 340 
measures of satisfaction with information or beliefs about medicines. There was a 341 
slight increase in the percentage of participants classed as adherent at the end of the 342 
study. This indicates that these measures may not be appropriate for a larger study.   343 
 344 
In a larger study, the primary outcome measure would be HbA1C and this would need 345 
to be collected for some time after the end of the study and any changes made 346 
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requested by the pharmacist as a result of the clinic would need to be followed-up to 347 
determine their implementation rate. The extent to which both of these can be 348 
achieved was not tested during this study. Adherence was characterised using a self-349 
report method which may be less reliable than other forms of adherence 350 
measurement e.g. prescription refill data [23]. Both HbA1C and refill data may be 351 
more useful outcome measures for a future study and would also reduce the 352 
participant questionnaire burden. Along with self-report adherence, participants self-353 
selected for this service and they were therefore more likely to be motivated to 354 
engage with an intervention aimed at their condition. However, despite this limitation 355 
the study only invited patients who were poorly controlled and therefore any 356 
improvement in their condition will be beneficial to the patient and the NHS.  357 
 358 
Participant satisfaction with the service was high with most suggesting that they 359 
thought it would help them manage their diabetes better and that this kind of service 360 
should be available to all patients. They identified that the pharmacists appeared 361 
knowledgeable, professional and approachable with some participants noting that the 362 
pharmacist did not appear to rush them and was not distracted by other work in the 363 
dispensary. This has previously been identified as a problem and may indicate a 364 
potential reason why a patient may not engage with the pharmacist [17]. One 365 
limitation of the questionnaire includes the phrasing of the questions regarding 366 
community pharmacy use in the last three months. Participants may have included 367 
the study consultation in their responses and therefore these results should be 368 
interpreted with caution.  369 
 370 
From the de-brief interviews, pharmacists stated that they enjoyed providing the 371 
drop-in clinic as it allowed them to use the knowledge that they had learnt from their 372 
training. This allowed them to interact with patients for longer and they especially 373 
enjoyed the feedback and hearing from patients about their progress once the study 374 
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had finished. In terms of the feedback on the consultation, the pharmacists identified 375 
that one of the most important aspects to the service was the dispensary support 376 
provided as part of the research. This enabled them to focus on the patient and not 377 
feel distracted by events in the dispensary. Another central point that the pharmacists 378 
focused on was the need to talk to the practice nurse or doctor about local treatment 379 
guidelines to ensure that they were not providing conflicting advice. This 380 
demonstrates the need for pharmacists to be better integrated within the primary 381 
healthcare team and is something the patients have identified as important [20].  382 
 383 
The study achieved a response rate of 9.6% from the postal invitation, something 384 
that has implications for generalisability of the results. A low response rate such as 385 
this may imply that only motivated patients were encouraged to participate in the 386 
study and therefore these patients may not be representative of the wider population 387 
with diabetes. This response rate for also has implications for calculating the required 388 
number of participants for a larger study.  389 
 390 
The consultations themselves lasted significantly longer than GP consultations [24] 391 
with the mean time at approximately 32 minutes. This allowed the pharmacist to 392 
spend longer with the participants discussing all aspects of their care but may prove 393 
an expensive intervention when compared to a similar nurse-led service [25], 394 
however the pharmacist is more likely to have capacity for this type of intervention. 395 
This could have implications for this type of community pharmacy service in primary 396 
care and means that there will need to be a further defining of the intervention in 397 
order to make it distinct from current nurse provision, which is less expensive. If 398 
pharmacists have the time to spend with patients in this manner, then it may be 399 
appropriate for the intervention to focus on using behaviour change techniques, 400 
which have been found to have a positive effect on adherence [26] rather than on a 401 
wider variety of (unfocussed) topics. 402 
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 403 
However, there still remain unanswered questions regarding the community 404 
pharmacist’s role in this group of patients, particularly with reference to the role of the 405 
practice or diabetes nurse in the UK. As a result of this work and the work of others 406 
[16], it appears sensible to undertake further exploratory work to determine the type 407 
of intervention pharmacists should be providing to this group of patients. 408 
 409 
Conclusion 410 
The diabetes community pharmacy drop-in clinic was well received by patients and 411 
pharmacists and was feasible to conduct in this particular setting. However, there still 412 
remain questions regarding the input of the community pharmacist in the care of this 413 
group of patients, particularly with such a strong nurse-led service already provided 414 
to them in the UK setting. With a significant number of patients still remaining 415 
uncontrolled with respect to national guidelines it is therefore appropriate to conduct 416 
further work to determine if and how the pharmacist can support the wider primary 417 
care team in improving treatment for patients with type 2 diabetes.  418 
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Figure 1 Responses that required a yes/no/not sure answer from the feedback questionnaire 
0 10 20 30 40 50 60 70 80 90 100
Did you find it useful to speak to the pharmacist about your condition?
Were you satisfied with the information you received during the
consultation?
Did you feel the information given was at a level that you could
understand?
Do you think this service, or a service like it, could be useful for other
patients with diabetes or other conditions?
Would you use this service again?
Would you recommend this service to other patients with type 2
diabetes?
Did you think that a direct leaflet was the best way to inform you of the
clinic? N=25
In terms of content, do you think the first questionnaire asked the right
questions for you?
Do you think the pharmacy was the right place for this type of clinic?
Do you think the pharmacist is the right person to conduct this type of
clinic?
% of patients responding 
Q
u
e
st
io
n
 
yes
no
not sure
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Table 1 Participant Demographics 
 N Mean (SD) 
% of patients 
uncontrolled 
Distance travelled to clinic (miles) 33 3.1 (2.7) n/a 
Most recent HbA1C result (mmol/mol) 27* 63.5 (13.2) 44.5 
Most recent SBP result (mmHg) 27* 133.6 (21.7) 74.1 
Most recent DBP result (mmHg) 27* 78.8 (16.1) 81.5 
Most recent total cholesterol result (mmol/L) 27* 4.4 (1.4) 48.1 
Number of medicines prescribed 29* 8.8 (4.2) n/a 
Years since diagnosis 29* 8.1 (5.0) n/a 
*Data unobtainable for some participants presenting at pharmacy 4. SBP: systolic blood pressure; 
DBP: diastolic blood pressure; data normally distributed.  
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Table 2 Baseline and follow-up questionnaire data 
Measure 
Before N=33  
(median (quartiles))* 
After N=26 
(median (quartiles))* 
BMQ – necessity scale /25 20 (17 – 23) 20 (17 – 22) 
BMQ – concerns scale /25 14 (11 – 18) 16 (12.75 – 18) 
BMQ – differential score 6 (2 – 9) 4.5 (-0.25 – 8.25) 
SIMS – actions and usage 
score /9 
7 (4 – 8) 7 (5 – 9) 
SIMS – potential problems 
score /8 
4 (2.5 – 7) 5.5 (2.25 – 7.25) 
SIMS – total score /17 11 (8 – 13) 11 (7.75 – 16) 
BMQ: beliefs about medicines; SIMS: satisfaction with information about medicines scale 
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Table 3 Community pharmacy use before and after the study 
Not counting today, how many 
times in the last three months 
have you: 
Before n=33 
Mean (SD) 
After n=26 
Mean (SD) 
  
 Visited the pharmacy 3.37 (2.82) 3.37 (2.65) 
 Spoken to the pharmacist 0.96 (1.54) 1.91 (2.51) 
What have you spoken to the 
pharmacist about? 
% responding ‘yes’ % responding ‘yes’ 
 Your condition 0 38.5 
 Your medication 15.2 34.6 
 Over-the-counter advice 18.2 23.1 
 Lifestyle 6.1 19.2 
 Dietary advice 9.1 26.9 
 Other medical conditions 12.1 26.9 
 Minor ailments 9.1 19.2 
 Medicine supply 21.2 53.8 
 
 
 
